Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 13/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 7/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PRCP | P42785 | 1/20 | 0.44 |
| ▸ | STAT6 | P42226 | 1/20 | 0.41 |
| ▸ | STAT5A | P42229 | 1/20 | 0.41 |
| ▸ | STAT5B | P51692 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17459564 | 1.00 | ACE (0.46) | ACEACE2TSHRPRCPSTAT6 | |
| SCHEMBL17968865 | 1.00 | ACE (0.46) | ACEACE2TSHRPRCPSTAT6 | |
| SCHEMBL19465507 | 1.00 | ACE (0.46) | ACEACE2TSHRPRCPSTAT6 | |
| SCHEMBL17834576 | 0.93 | ACE (0.49) | ACEACE2TSHRPRCP | |
| SCHEMBL15037081 | 0.92 | ACE (0.46) | ACEACE2TSHRPRCP | |
| SCHEMBL15037086 | 0.92 | ACE (0.46) | ACEACE2TSHRPRCP | |
| SCHEMBL17459612 | 0.91 | ACE (0.46) | ACEACE2TSHRPRCPSTAT6 | |
| SCHEMBL17459610 | 0.91 | ACE (0.46) | ACEACE2TSHRPRCPSTAT6 | |
| SCHEMBL19465512 | 0.91 | ACE (0.46) | ACEACE2TSHRPRCPSTAT6 | |
| SCHEMBL17459609 | 0.91 | ACE (0.46) | ACEACE2TSHRPRCPSTAT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3230276-B1 | GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-09-02 | — | — | EP | disclosed |
| US-10034886-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2018-07-31 | — | — | US | disclosed |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2018-01-25 | — | — | US | disclosed |
| US-9795613-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-10-24 | — | — | US | disclosed |
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | ACE 3137/4885ACE2 3162/4885TSHR 45/4885 |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | ACE 3137/4885ACE2 3162/4885TSHR 45/4885 |
| US-10034886-B2 | GLP-1 receptor modulators | GLP1R, GIPR, GCGR | ACE 2924/4885ACE2 3115/4885TSHR 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.